Evidence mapPaperPMID 37848671Full record

ArticleApoptosis : an international journal on programmed cell death2024

N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer.

Yao Peng, Zhili Zhang, Gongli Yang, Zhongming Dai, Xunchao Cai, Zhenyu Liu, Qian Yun, Long Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. circATAD2 mitigates CD8Cancer immunology, immunotherapy : CII · 2024
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yao PengDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Zhili ZhangDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Gongli YangDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Zhongming DaiDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Xunchao CaiDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Zhenyu LiuDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Qian YunDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China.
Long XuDepartment of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China. dr_xulongphd@yeah.net.
Shenzhen University · CNShenzhen University Health Science Center · CNSouthern Medical University Shenzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor immune escape is an important manner for colon cancer to escape effective killing by immune system. Currently, the immune checkpoint PD-1/PD-L1-targeted immunotherapy has emerged as a promising therapeutic strategy in colon cancer. Here, present work aims to investigate the biological function of N

Indexed as

CD8-Positive T-LymphocytesColonic NeoplasmsApoptosisB7-H1 AntigenHumansRNA, MessengerB7-H1 AntigenRNA, Messengercolon cancerIGF2BP1.Immune escapeN6-methyladenosinePD-L1

Identifiers

PMID37848671
OpenAlexW4387701658

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.